Eli Lilly: Sofe-M combined with bevacizumab treated ovarian cancer, with an objective response rate of 79%.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.